CJC-1295
A growth hormone releasing hormone analogue. The 'with DAC' version lasts days rather than minutes.
Not approved anywhere
| What it is | A modified fragment of growth hormone releasing hormone. The DAC version adds a chemistry that binds it to albumin so it persists far longer. |
|---|---|
| How it is thought to work | Stimulates the pituitary to release growth hormone, through a different receptor than ipamorelin — which is the reason the two are often paired. |
| What the evidence actually shows | Early-phase human pharmacokinetic studies showed it does raise GH and IGF-1. There are no trials showing a clinical benefit for tissue repair or hypermobility. |
| Regulatory status | Not approved. Development did not continue to approval. |
| Dosing | No approved dose. Published early-phase studies were dose-ranging pharmacokinetic work, not treatment protocols. |
| In the catalog as |
Risks and cautions
- The DAC version's long half-life means a continuous elevation in GH rather than the pulses the body normally produces. The long-term consequence of that is not known.
- Same cancer and blood sugar considerations as any GH-raising compound.
- Prohibited in sport by WADA.
Before you act on any of this
This page describes what is known and what is not. It is not a recommendation to use anything, and it is not a protocol. Compounds listed as research chemicals are not approved medicines and are not sold for human use. Talk to a doctor who knows your history.